Jeil Pharmaceutical Co.,Ltd (271980.KS)
KRW 11640.0
(-5.6%)
KRW 11640.0
(-5.6%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 726.39 Billion | 722.22 Billion | 700.69 Billion | 691.32 Billion | 671.4 Billion | 627.07 Billion |
| Cost of Revenue | 542.57 Billion | 565.43 Billion | 544.71 Billion | 534.63 Billion | 519.48 Billion | 488.44 Billion |
| Gross Profit | 183.81 Billion | 156.79 Billion | 155.97 Billion | 156.69 Billion | 151.92 Billion | 138.63 Billion |
| Operating Expenses | 174.92 Billion | 170.13 Billion | 166.35 Billion | 143.78 Billion | 151.54 Billion | 131.24 Billion |
| Selling, General and Administrative Expenses | 76.48 Billion | 74.63 Billion | 74.72 Billion | 70.38 Billion | 71.15 Billion | 57.77 Billion |
| Research and Development Expenses | 45.72 Billion | 41.14 Billion | 38.97 Billion | 24.27 Billion | 22.11 Billion | 24.87 Billion |
| Other Expenses | 53.31 Billion | 54.35 Billion | 52.65 Billion | 49.13 Billion | 58.27 Billion | 696.77 Million |
| Cost and Expenses | 717.5 Billion | 735.56 Billion | 711.07 Billion | 678.42 Billion | 671.03 Billion | 619.68 Billion |
| Operating Income | 8.73 Billion | -13.33 Billion | -5.63 Billion | 12.9 Billion | 1.05 Billion | 7.39 Billion |
| Interest Expense | 6.03 Billion | 3 Billion | 1.96 Billion | 1.07 Billion | 1.21 Billion | 1.59 Billion |
| Income Tax Expense | -3.28 Billion | 1.76 Billion | 1.15 Billion | 5.58 Billion | 9.64 Billion | 2.99 Billion |
| Earnings before Tax | 1.91 Billion | -13.24 Billion | -13.83 Billion | 12.55 Billion | -940.85 Million | 4.88 Billion |
| Net Income | 5 Billion | -15 Billion | -14.98 Billion | 6.91 Billion | -10.58 Billion | 1.88 Billion |
| Earnings Per Share Basic | 343.00 | -1029.79 | -1025.79 | 473.24 | -721.28 | 142.00 |
| Earnings Per Share Diluted | 343.46 | -1029.79 | -1025.79 | 473.24 | -721.28 | 142.00 |
| Weighted Average Shares Outstanding | 14.59 Million | 14.57 Million | 14.6 Million | 14.61 Million | 14.67 Million | 13.3 Million |
| Weighted Average Shares Outstanding (Diluted) | 14.57 Million | 14.57 Million | 14.6 Million | 14.61 Million | 14.67 Million | 13.3 Million |
| Gross Margin | 0.25 | 0.22 | 0.22 | 0.23 | 0.23 | 0.22 |
| EBIT Margin | 0.03 | -0.01 | 0.00 | 0.03 | 0.01 | 0.02 |
| Profit Margin | 0.01 | -0.02 | -0.02 | 0.01 | -0.02 | 0.00 |
| EBITDA | 18.65 Billion | -1.2 Billion | -2.01 Billion | 22.59 Billion | 8.5 Billion | 13.11 Billion |
| Earnings Before Tax Margin | 0.01 | -0.02 | -0.01 | 0.02 | 0.00 | 0.01 |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | 173.17 Billion | 170.41 Billion | 179.66 Billion | 726.39 Billion | 177.2 Billion | 178.46 Billion |
| Cost of Revenue | 129.33 Billion | 128.69 Billion | 135.6 Billion | 542.57 Billion | 136.96 Billion | 136.74 Billion |
| Gross Profit | 43.84 Billion | 41.71 Billion | 44.06 Billion | 183.81 Billion | 40.24 Billion | 41.72 Billion |
| Operating Expenses | 58.99 Billion | 43.99 Billion | 45.53 Billion | 174.92 Billion | 42.83 Billion | 44.94 Billion |
| Selling, General and Administrative Expenses | 29.08 Billion | 33.13 Billion | 33.23 Billion | - | 18.89 Billion | 19.41 Billion |
| Research and Development Expenses | 10.64 Billion | 10.7 Billion | 12.14 Billion | - | 10.63 Billion | 12.91 Billion |
| Other Expenses | -19.26 Billion | -151.45 Million | -148.37 Million | -511.82 Million | -552.36 Million | 209.15 Million |
| Cost and Expenses | 188.32 Billion | 172.69 Billion | 181.14 Billion | 717.5 Billion | 179.8 Billion | 181.68 Billion |
| Operating Income | -15.14 Billion | -2.27 Billion | -1.47 Billion | 8.88 Billion | -2.65 Billion | -3.21 Billion |
| Interest Expense | 1.29 Billion | 1.6 Billion | 1.44 Billion | 6.03 Billion | 1.63 Billion | 1.56 Billion |
| Income Tax Expense | 4.74 Billion | 339.58 Million | -3.96 Billion | -3.28 Billion | 116.7 Million | 536.18 Million |
| Earnings before Tax | -22.81 Billion | -2.93 Billion | -6.89 Billion | 1.1 Billion | -4.5 Billion | -1.21 Billion |
| Net Income | -26.51 Billion | -2.87 Billion | -2.23 Billion | 5 Billion | -4.11 Billion | -1.34 Billion |
| Earnings Per Share Basic | -1819.49 | -197.50 | -153.53 | - | -282.14 | -92.61 |
| Earnings Per Share Diluted | -1819.49 | -197.50 | -153.53 | - | -282.14 | -92.61 |
| Weighted Average Shares Outstanding | 14.57 Million | 14.57 Million | 14.57 Million | 14.57 Million | 14.57 Million | 14.57 Million |
| Weighted Average Shares Outstanding (Diluted) | 14.57 Million | 14.57 Million | 14.57 Million | 14.57 Million | 14.57 Million | 14.57 Million |
| Gross Margin | 0.25 | 0.24 | 0.25 | 0.25 | 0.23 | 0.23 |
| EBIT Margin | -0.07 | 0.00 | 0.01 | - | -0.00 | 0.00 |
| Profit Margin | -0.15 | -0.02 | -0.01 | 0.01 | -0.02 | -0.01 |
| EBITDA | -12.24 Billion | 398.84 Million | 1.11 Billion | - | -490.15 Million | 568.31 Million |
| Earnings Before Tax Margin | -0.09 | -0.01 | -0.01 | 0.01 | -0.01 | -0.02 |
000670
CIM
MONEYBOXX
1429
FRS
FIBI